Literature DB >> 18299406

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Francis F Arhin1, Ingrid Sarmiento, Adam Belley, Geoffrey A McKay, Deborah C Draghi, Parveen Grover, Daniel F Sahm, Thomas R Parr, Gregory Moeck.   

Abstract

Oritavancin, a semisynthetic lipoglycopeptide with activity against gram-positive bacteria, has multiple mechanisms of action, including the inhibition of cell wall synthesis and the perturbation of the membrane potential. Approved guidelines for broth microdilution MIC assays with dalbavancin, another lipoglycopeptide, require inclusion of 0.002% polysorbate 80. To investigate the potential impact of polysorbate 80 on oritavancin susceptibility assays, we quantified the recovery of [(14)C]oritavancin from susceptibility assay plates with and without polysorbate 80 and examined the effect of the presence of polysorbate 80 on the oritavancin MICs for 301 clinical isolates from the genera Staphylococcus, Enterococcus, and Streptococcus. In the absence of polysorbate 80, [(14)C]oritavancin was rapidly lost from solution in susceptibility assay test plates: 9% of the input drug was recovered in broth at 1 h when [(14)C]oritavancin was tested at 1 mug/ml. Furthermore, proportionately greater losses were observed at lower oritavancin concentrations, suggesting saturable binding of oritavancin to surfaces. The inclusion of 0.002% polysorbate 80 or 2% lysed horse blood permitted the recovery of 80 to 100% [(14)C]oritavancin at 24 h for all drug concentrations tested. Concordantly, oritavancin MIC(90)s for streptococcal isolates, as determined in medium containing 2% lysed horse blood, were identical with and without polysorbate 80. In stark contrast, polysorbate 80 reduced the oritavancin MIC(90)s by 16- to 32-fold for clinical isolates of enterococci and staphylococci, which are typically cultured without blood. The results presented here provide evidence that the MIC data for oritavancin in the current literature significantly underestimate the potency of oritavancin in vitro. Moreover, the combination of data from MIC and [(14)C]oritavancin recovery studies supports the revision of the oritavancin broth microdilution method to include polysorbate 80 throughout the assay.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18299406      PMCID: PMC2346630          DOI: 10.1128/AAC.01513-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.

Authors:  Ronald N Jones; Jennifer M Streit; Thomas R Fritsche
Journal:  Int J Antimicrob Agents       Date:  2004-02       Impact factor: 5.283

2.  Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors:  Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

3.  Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.

Authors:  Thomas R Fritsche; Robert P Rennie; Beth P Goldstein; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.

Authors:  Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

5.  In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

Authors:  R Patel; M S Rouse; K E Piper; F R Cockerill; J M Steckelberg
Journal:  Diagn Microbiol Infect Dis       Date:  1998-02       Impact factor: 2.803

6.  Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs.

Authors:  M T Kenny; M A Brackman
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

7.  Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Authors:  Ronald N Jones; Matthew G Stilwell; Helio S Sader; Thomas R Fritsche; Beth P Goldstein
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01-19       Impact factor: 2.803

8.  Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.

Authors:  S A Zelenitsky; B Booker; N Laing; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

9.  Ramoplanin susceptibility testing criteria.

Authors:  A L Barry; M A Pfaller; P C Fuchs
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

10.  Effect of protein on ramoplanin broth microdilution minimum inhibitory concentrations.

Authors:  R Scotti; J K Dulworth; M T Kenny; B P Goldstein
Journal:  Diagn Microbiol Infect Dis       Date:  1993-10       Impact factor: 2.803

View more
  37 in total

1.  Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Authors:  Ronald N Jones; John D Turnidge; Greg Moeck; Francis F Arhin; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.

Authors:  David J Farrell; Rodrigo E Mendes; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 3.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

4.  Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.

Authors:  Rodrigo E Mendes; Helio S Sader; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

5.  A new antibiotic kills pathogens without detectable resistance.

Authors:  Losee L Ling; Tanja Schneider; Aaron J Peoples; Amy L Spoering; Ina Engels; Brian P Conlon; Anna Mueller; Till F Schäberle; Dallas E Hughes; Slava Epstein; Michael Jones; Linos Lazarides; Victoria A Steadman; Douglas R Cohen; Cintia R Felix; K Ashley Fetterman; William P Millett; Anthony G Nitti; Ashley M Zullo; Chao Chen; Kim Lewis
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

6.  Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.

Authors:  Ronald N Jones; Greg Moeck; Francis F Arhin; Michael N Dudley; Paul R Rhomberg; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum.

Authors:  Joseph W Ndieyira; Natascha Kappeler; Stephen Logan; Matthew A Cooper; Chris Abell; Rachel A McKendry; Gabriel Aeppli
Journal:  Nat Nanotechnol       Date:  2014-03-02       Impact factor: 39.213

8.  The genome insights of Streptomyces lannensis T1317-0309 reveals actinomycin D production.

Authors:  Ram Hari Dahal; Tuan Manh Nguyen; Ramesh Prasad Pandey; Tokutaro Yamaguchi; Jae Kyung Sohng; Jongsung Noh; Seung-Woon Myung; Jaisoo Kim
Journal:  J Antibiot (Tokyo)       Date:  2020-07-09       Impact factor: 2.649

9.  A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.

Authors:  Laura M Koeth; Jeanna M DiFranco-Fisher; Sandra McCurdy
Journal:  J Vis Exp       Date:  2015-09-09       Impact factor: 1.355

10.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Anne Theunis; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.